Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will be the featured speaker in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The conference will take place September 4-6, 2024, in New York City.
2024年8月28日,美國加利福尼亞州聖地亞哥 / PRNewsWire -- Viking Therapeutics,Inc.("Viking")(納斯達克:VKTX),一家專注於開發新型代謝和內分泌疾病治療的臨床階段生物製藥公司,宣佈其首席執行官Brian Lian博士將成爲摩根士丹利第22屆全球醫療保健大會特邀演講嘉賓。該會議將於2024年9月4日至6日在紐約舉行。
Details are as follows:
詳細信息如下:
-
Morgan Stanley 22nd Annual Global Healthcare Conference
Details: Dr. Lian will participate in a fireside chat and in 1-on-1 meetings
Conference dates: September 4-6, 2024
Fireside Chat Timing: 1:50 – 2:25 p.m. Eastern on Wednesday, September 4, 2024
Location: New York Marriott Marquis
- 摩根士丹利第22屆全球醫療保健大會
詳情:Lian博士將參與會談和一對一會議
會議日期:2024年9月4日至6日
會談時間:2024年9月4日星期三下午1:50 - 2:25(美東時間)
地點:紐約萬豪酒店
A live webcast of the fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
演講會的實時網絡直播可以通過Viking Therapeutics網站的"投資者與媒體"欄目下的鏈接進行訪問。此外,會議結束後,演講會的回放將在Viking網站上提供。
About Viking Therapeutics, Inc.
美國維京療法公司是一家臨床階段的生物製藥公司,專注於開發治療代謝和內分泌疾病的新型療法。
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD.
Viking Therapeutics,Inc.是一家臨床階段的生物製藥公司,專注於開發治療代謝和內分泌疾病的新型一流或最好的療法,目前有三個化合物正在進行臨床試驗。Viking的研發活動利用了其在代謝方面的專業知識,開發了旨在改善患者生活的創新治療藥物。Viking的臨床項目包括VK2735,一種新型的胰高血糖素樣肽1(GLP-1)和葡萄糖依賴性胰島素促生肽(GIP)受體雙激動劑,用於潛在的各種代謝性疾病的治療。對VK2735(皮下注射給藥)進行的一期和二期試驗的數據顯示出令人鼓舞的安全性和耐受性,以及積極的臨床效益跡象。同時,公司正在評估VK2735的口服制劑在一期試驗中的應用。Viking還正在開發VK2809,一種新型的口服小分子選擇性甲狀腺激素受體β激動劑,用於治療脂質和代謝性疾病。該化合物在治療活檢確認的非酒精性脂肪肝炎(NASH)和纖維化的二十億期研究中成功實現了一級和二級終點。在治療非酒精性脂肪肝病(NAFLD)和高低密度脂蛋白膽固醇(LDL-C)的二期a期試驗中,接受VK2809治療的患者與接受安慰劑的患者相比,低密度脂蛋白膽固醇(LDL-C)和肝脂含量均顯著降低。公司最新的項目是評估一系列內部開發的雙氨酰素和降鈣素受體激動劑(或DACRAs)用於肥胖和其他代謝性疾病的治療。在罕見疾病領域,Viking正在開發VK0214,一種新型的口服小分子選擇性甲狀腺激素受體β激動劑,用於潛在的X連鎖皮質醇浸潤性腦白質營養不良(X-ALD)的治療。VK0214目前正在進行一期十億臨床試驗,用於治療X-ALD的脊髓運動神經病變(AMN)型患者。
For more information about Viking Therapeutics, please visit .
了解更多關於美國維京療法公司的信息,請訪問。
SOURCE Viking Therapeutics, Inc.
來源:美國維京療法公司。